# Cagrilintide: Acylated Amylin Analogue Structure, Receptor Logic and Research Use > Why the amylin axis needs its own reference compound — cagrilintide's aggregation-resistant backbone, its non-selective receptor profile, and the handling it demands. Web page: https://peptidemedixeu.com/en/learn/what-is-cagrilintide/ · Peptide Medix EU · 6 min read · Updated: 2026-04-23 Engineered for stability and for broad activity across the amylin and calcitonin receptor family, [cagrilintide](https://peptidemedixeu.com/en/products/cagrilintide/) is a long-acting acylated analogue of amylin, the pancreatic hormone secreted alongside insulin by beta cells. Its importance in metabolic research is that it signals through a pathway quite separate from the [incretin receptor family](https://peptidemedixeu.com/en/glossary/incretin/), which makes it the default instrument for asking what the amylin axis adds on top of GLP-1 signalling. Our research-grade cagrilintide comes as lyophilized powder in sealed vials, for laboratory use only. Cagrilintide remains investigational. As of 2026 it has no marketing approval anywhere, and research-grade material is a reference chemical, not a medicine. ## Defining cagrilintide Human amylin — islet amyloid polypeptide, or IAPP — is a 37-residue peptide secreted with insulin in response to nutrients. Two of its characteristics make the native molecule useless as a research tool: a [half-life in plasma measured in minutes](https://peptidemedixeu.com/en/glossary/half-life/) and a pronounced tendency to aggregate into amyloid fibrils, the very fibrils present in the islets of people with type 2 diabetes. Any workable amylin analogue must overcome both at once. The earlier analogue [pramlintide](https://peptidemedixeu.com/en/products/pramlintide/) handled aggregation by adopting proline substitutions from rat amylin, which does not fibrillate, but it stayed short-acting. Cagrilintide — AM833 in the literature — addresses both problems: a non-aggregating analogue bearing a fatty-acid side chain for albumin binding, which gives it a duration measured in days. ## Origin and structure - A backbone derived from amylin, with substitutions that break up the beta-sheet stacking that drives amyloid formation. - An intramolecular disulfide linking the two N-terminal cysteines, creating the small ring that both native amylin and calcitonin need for receptor activity — the reason two sulfur atoms appear in the formula. - An amidated C-terminus, as in native amylin, required for receptor engagement. - Fatty-acid acylation on a lysine side chain, which provides reversible albumin binding and the extended circulating persistence seen in pharmacokinetic studies. - A non-selective receptor profile, with reported activity at AMY1, AMY2 and AMY3 as well as at the calcitonin receptor itself. Catalogue identifiers: CAS 1415456-99-3, formula C194H309N55O59S2, molecular weight 4409.07 Da. ## The proposed mechanism Amylin receptors are not ordinary stand-alone GPCRs but heterodimers, formed when the calcitonin receptor (CTR) associates with one of three receptor activity-modifying proteins — RAMP1, RAMP2 or RAMP3 — to give AMY1, AMY2 and AMY3 in turn. The RAMP partner remodels the ligand-binding pocket so that one core receptor comes to prefer amylin over calcitonin. There is an immediate implication for experimental design: putting CTR alone into a cell line does not create an amylin receptor, and whichever RAMP subtype is present dictates the pharmacology you observe. Downstream signalling is reported as Gs-coupled cAMP accumulation, with the relevant receptor populations concentrated in the area postrema and nucleus tractus solitarius — hindbrain areas lying outside the tight blood-brain barrier. Preclinical studies describe lower food intake and slower gastric emptying after amylin receptor agonism, effects usually credited to those hindbrain populations. Since that circuitry differs both anatomically and pharmacologically from the hypothalamic and vagal GLP-1 receptor populations, amylin and GLP-1 agonists are reported to act additively rather than redundantly in animal models, which is the reasoning behind co-administration studies combining cagrilintide with semaglutide. Within this family, selectivity is an open design problem rather than a settled matter. An agonist that hits AMY1, AMY2, AMY3 and the calcitonin receptor alike gives a composite response, and calcitonin receptor activation brings its own biology in bone and elsewhere. Selective [analogues of amylin](https://peptidemedixeu.com/en/blog/cagrisema-amylin-analogs-researchers-pair-cagrilintide-semaglutide/) are under development precisely to pull those contributions apart, so a laboratory selecting cagrilintide should understand that it answers what broad amylin-family agonism does, not what AMY3 alone does. When the goal is attributing an effect to a subtype, RAMP-defined [cell lines expressing recombinant receptors](https://peptidemedixeu.com/en/glossary/recombinant/) and subtype-selective comparators are the right tools. ## What has been studied - Receptor pharmacology. Binding and cAMP assays in cells co-expressing CTR with RAMP1, 2 or 3, used to define the non-selective profile that sets cagrilintide apart from selective amylin analogues. - Biophysics and aggregation. Thioflavin T fibrillation assays, circular dichroism and stability testing — central to work on any amylin analogue, since aggregation propensity is this family's defining weakness. - Rodent studies. Food intake, gastric emptying and body composition in diet-induced obesity models, together with combination experiments probing additivity with GLP-1 receptor agonists. - Human clinical trials. Phase 1 and 2 results have been published for cagrilintide by itself and in fixed combination with semaglutide, and phase 3 programmes have reported outcomes. All of this concerns an investigational pharmaceutical used under clinical supervision and does not apply to research-grade material. Our note on why researchers pair cagrilintide with semaglutide sets out the combination rationale. One methodological caution applies to amylin work generally. At the low nanomolar concentrations used in receptor assays, adsorption of peptide to glass and polypropylene is substantial, and loss by adsorption looks exactly like low potency on the resulting curve. Carrier protein in the buffer, low-binding plasticware and dilutions made fresh are the standard countermeasures, and neglecting them is a frequent reason published potency values for amylin analogues differ between laboratories by an order of magnitude or more, even with the same nominal compound and receptor construct. ## Presentations available Sizes and prices appear on the cagrilintide product page, filed under the GLP-1 and incretin peptides collection because most laboratories buying it are doing incretin comparisons. ## Reconstitution and storage at the bench The usual concentration arithmetic applies: reconstituting a 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL, equivalent to 2,500 mcg/mL, so 0.1 mL of that solution holds 250 mcg of peptide. Handling, though, calls for more care than an ordinary acylated peptide. Amylin-family sequences keep a residual tendency to aggregate even after being engineered against it, and mechanical agitation, low concentrations on untreated plastic and a pH close to the [isoelectric point all encourage](https://peptidemedixeu.com/en/glossary/isoelectric-point/) it. Introduce the diluent gently against the vial wall, swirl instead of shaking, and check the solution for haze or fibres before use — cloudiness in an amylin analogue preparation means the preparation has failed, not that it looks untidy. Sealed lyophilized powder is stable at minus 20 degrees Celsius, away from light and moisture. Keep reconstituted solution at 2 to 8 degrees Celsius and use it inside the study window; because aggregation depends on both time and temperature, minimising the delay between reconstitution and use matters more here than with incretin peptides. See our reconstitution guide, storage guide. ## Purity, the COA and how to read it A cagrilintide certificate ought to carry an HPLC chromatogram with the main-peak area percentage, a mass spectrometry identity result compared against the theoretical 4409.07 Da, net peptide content, the lot number and the analysis date. One further check belongs to this molecule specifically: the disulfide must be correctly formed, and a reduced or scrambled variant is only two mass units from the intended structure — a gap a low-resolution spectrum can overlook. Where your assay hinges on disulfide integrity, ask what the analysis genuinely resolved. The remainder is covered in our guide to [interpreting a certificate of analysis](https://peptidemedixeu.com/en/blog/read-peptide-coa-like-chemist/). [How prepared working solutions are kept](https://peptidemedixeu.com/en/learn/how-to-store-peptides/) deserves a closing remark. Among peptide classes, the amylin family is where the interval between preparation and use shows up in the data most reliably, because aggregation advances slowly enough to be invisible at preparation yet far enough to matter hours later. Laboratories that log preparation time next to experiment time, and that treat any solution older than the validated window as a fresh preparation rather than the original one, eliminate a source of drift that is otherwise easily mistaken for biological variability. That same discipline accounts for much of the disagreement between amylin studies run in different laboratories. ## Regulatory position Cagrilintide is an investigational compound and holds no marketing approval in any jurisdiction as of 2026. The published clinical data describe a trial product and open no route to human use for laboratory material. ## Related peptides and comparisons Pairing it with a GLP-1 receptor agonist is the most common approach, discussed in cagrilintide vs semaglutide. Anyone comparing amylin analogues will also want pramlintide, its short-acting predecessor. For work spanning several incretin receptors, see retatrutide. ## Frequently asked questions ### What is cagrilintide based on? It derives from human amylin, the 37-residue peptide released together with insulin by pancreatic beta cells. Cagrilintide preserves the amylin pharmacophore — the N-terminal disulfide ring and the amidated C-terminus — while introducing substitutions that block fibril formation plus a fatty-acid side chain that prolongs its time in circulation. ### Why must amylin analogues be engineered against aggregation? Human amylin self-assembles easily into amyloid fibrils, the deposits seen in diabetic islets. An analogue that fibrillates is worthless as a reagent: it drops out of solution and its working concentration can no longer be known. Every usable amylin analogue therefore carries substitutions that disrupt the beta-sheet stacking behind that process. ### Which receptors does cagrilintide activate? Amylin receptors are heterodimers pairing the calcitonin receptor with RAMP1, RAMP2 or RAMP3 to give AMY1, AMY2 and AMY3. Cagrilintide is reported to act across all three without selectivity, and also at the calcitonin receptor on its own. Note that expressing the calcitonin receptor without a RAMP does not yield an amylin receptor. ### Why is cagrilintide often studied together with semaglutide? The two pathways are separate and so is their anatomy — amylin receptors cluster in the area postrema, while GLP-1 receptors are spread across hypothalamic and vagal populations. Preclinical results describe effects that add up rather than overlap, which is why combination studies exist and why cagrilintide serves as an add-on comparator in incretin research. ### Has cagrilintide been approved? No. As of 2026 no jurisdiction has granted it marketing approval. Published phase 1 to 3 data concern the investigational product, alone and in fixed combination, whereas research-grade cagrilintide is a laboratory reference chemical with no authorisation for human use. ### Does it need handling different from an incretin peptide? To a degree. Because some aggregation tendency remains, reconstitute it gently, never shake it, look for haze or fibres before use, and keep the gap between reconstitution and use short. Storage itself is conventional: minus 20 degrees Celsius for sealed lyophilized material, 2 to 8 degrees Celsius once dissolved. ### Which additional check belongs on its certificate? Integrity of the disulfide. Receptor activity depends on that intramolecular bridge, and a reduced or scrambled version sits just two mass units away from the correct structure. Where your assay relies on an intact ring, confirm that the analytical method used could actually tell the two apart. ## Related products - [Cagrilintide](https://peptidemedixeu.com/en/products/cagrilintide/): from €97 --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.